Literature DB >> 15100295

Cathepsin E: a novel target for regulation by class II transactivator.

Christina S K Yee1, Yongxue Yao, Ping Li, Michael J Klemsz, Janice S Blum, Cheong-Hee Chang.   

Abstract

The aspartic proteinase cathepsin E (CatE) has been implicated in Ag processing. In this study we report that CatE expression is negatively regulated by the MHC class II transactivator (CIITA). CIITA-deficient murine and human B cells expressed greater CatE than wild-type B cells, whereas overexpression of CIITA in a human gastric carcinoma cell line, AGS, resulted in decreased CatE mRNA and protein. AGS cells expressing CIITA also exhibited decreased processing of OVA Ag. Inhibition of CatE expression is specific to the type III CIITA isoform and maps to the acidic and proline/serine/threonine-rich (PST) protein domains of CIITA. We found that CatE expression is inducible by PU.1 and p300, and that this induction can be reversed by CIITA. These findings demonstrate a novel phenomenon: regulation of CatE Ag processing by CIITA in an isoform-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15100295     DOI: 10.4049/jimmunol.172.9.5528

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Phosphorylation and ubiquitination of degron proximal residues are essential for class II transactivator (CIITA) transactivation and major histocompatibility class II expression.

Authors:  Kavita Purnanda Bhat; Agnieszka Dorota Truax; Susanna Fletcher Greer
Journal:  J Biol Chem       Date:  2010-06-10       Impact factor: 5.157

2.  Interferon-gamma induces major histocompatibility class II transactivator (CIITA), which mediates collagen repression and major histocompatibility class II activation by human aortic smooth muscle cells.

Authors:  Giovanna Butticè; Janice Miller; Lin Wang; Barbara D Smith
Journal:  Circ Res       Date:  2006-01-26       Impact factor: 17.367

3.  Gamma interferon modulates myogenesis through the major histocompatibility complex class II transactivator, CIITA.

Authors:  Priya Londhe; Judith K Davie
Journal:  Mol Cell Biol       Date:  2011-05-16       Impact factor: 4.272

4.  Potential biological functions of cytochrome P450 reductase-dependent enzymes in small intestine: novel link to expression of major histocompatibility complex class II genes.

Authors:  Jaime D'Agostino; Xinxin Ding; Peng Zhang; Kunzhi Jia; Cheng Fang; Yi Zhu; David C Spink; Qing-Yu Zhang
Journal:  J Biol Chem       Date:  2012-03-27       Impact factor: 5.157

5.  Collagen alpha1(I) gene (COL1A1) is repressed by RFX family.

Authors:  Pritam Sengupta; Yong Xu; Lin Wang; Russell Widom; Barbara D Smith
Journal:  J Biol Chem       Date:  2005-03-23       Impact factor: 5.157

6.  The effect of class II transactivator mutations on bleomycin-induced lung inflammation and fibrosis.

Authors:  Yong Xu; Larry Luchsinger; Edgar C Lucey; Barbara D Smith
Journal:  Am J Respir Cell Mol Biol       Date:  2010-08-12       Impact factor: 6.914

7.  Inhibition of human T cell leukemia virus type 2 replication by the suppressive action of class II transactivator and nuclear factor Y.

Authors:  Giovanna Tosi; Elisabetta Pilotti; Lorenzo Mortara; Andrea De Lerma Barbaro; Claudio Casoli; Roberto S Accolla
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-14       Impact factor: 11.205

8.  The contribution of cell phenotype to the behavior of gastric cancer.

Authors:  Enrico Solcia; Catherine Klersy; Alessandro Vanoli; Federica Grillo; Rachele Manca; Francesca Tava; Ombretta Luinetti; Roberto Fiocca
Journal:  Gastric Cancer       Date:  2013-01-18       Impact factor: 7.370

9.  Regulation of the human cathepsin E gene by the constitutive androstane receptor.

Authors:  Jeanine L Page; Stephen C Strom; Curtis J Omiecinski
Journal:  Arch Biochem Biophys       Date:  2007-08-19       Impact factor: 4.013

10.  Bone marrow-induced Mef2c deficiency delays B-cell development and alters the expression of key B-cell regulatory proteins.

Authors:  Irina Debnath; Kirstin M Roundy; Peter D Pioli; Janis J Weis; John H Weis
Journal:  Int Immunol       Date:  2012-10-19       Impact factor: 4.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.